Urteste（URT）株式概要Urteste S.A.は癌の診断テストの研究開発に従事している。 詳細URT ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析収益が 100 万ドル未満 ( PLN3M )過去5年間で収益は年間9.4%減少しました。 意味のある時価総額がありません ( PLN61M )Polish市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るURT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValuezłCurrent Pricezł43.202.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-8m21m2016201920222025202620282031Revenue zł20.7mEarnings zł3.8mAdvancedSet Fair ValueView all narrativesUrteste S.A. 競合他社Read-GeneSymbol: WSE:RDGMarket cap: zł59.7mGenomed Spólka AkcyjnaSymbol: WSE:GENMarket cap: zł31.7mTecnovaticaSymbol: WSE:TECMarket cap: zł7.4mSynthaverseSymbol: WSE:SVEMarket cap: zł206.7m価格と性能株価の高値、安値、推移の概要Urteste過去の株価現在の株価zł43.2052週高値zł81.6052週安値zł24.00ベータ0.231ヶ月の変化-0.92%3ヶ月変化-21.17%1年変化-45.32%3年間の変化-64.59%5年間の変化n/aIPOからの変化-56.28%最新ニュースNew Risk • Dec 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł5.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.8m revenue, or US$496k). Minor Risk Market cap is less than US$100m (zł49.3m market cap, or US$13.6m).お知らせ • Aug 25Urteste S.A. to Report First Half, 2025 Results on Sep 29, 2025Urteste S.A. announced that they will report first half, 2025 results on Sep 29, 2025お知らせ • Jul 21Urteste S.A. Completes the Development Phase of Panuri Test and Reached Technological Readiness for Clinical Performance StudyUrteste S.A. has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer - one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents with confirmed structure and purity, as well as reproducible test performance. The result-reading process has also been automated. As a result, the Panuri test complies with the IVDR - Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł15m free cash flow). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.5m revenue, or US$410k). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (zł80.6m market cap, or US$21.5m).お知らせ • May 29Urteste S.A., Annual General Meeting, Jun 25, 2025Urteste S.A., Annual General Meeting, Jun 25, 2025.分析記事 • May 27Here's Why We're Watching Urteste's (WSE:URT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...最新情報をもっと見るRecent updatesNew Risk • Dec 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł5.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.8m revenue, or US$496k). Minor Risk Market cap is less than US$100m (zł49.3m market cap, or US$13.6m).お知らせ • Aug 25Urteste S.A. to Report First Half, 2025 Results on Sep 29, 2025Urteste S.A. announced that they will report first half, 2025 results on Sep 29, 2025お知らせ • Jul 21Urteste S.A. Completes the Development Phase of Panuri Test and Reached Technological Readiness for Clinical Performance StudyUrteste S.A. has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer - one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents with confirmed structure and purity, as well as reproducible test performance. The result-reading process has also been automated. As a result, the Panuri test complies with the IVDR - Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł15m free cash flow). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.5m revenue, or US$410k). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (zł80.6m market cap, or US$21.5m).お知らせ • May 29Urteste S.A., Annual General Meeting, Jun 25, 2025Urteste S.A., Annual General Meeting, Jun 25, 2025.分析記事 • May 27Here's Why We're Watching Urteste's (WSE:URT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Dec 07Is Urteste (WSE:URT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Jul 19Urteste (WSE:URT) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...お知らせ • May 29Urteste S.A. Successfully Develops A Prototype Urine-Based Diagnostic Test for Detecting Brain TumoursUrteste S.A. developed a prototype IVD test for detecting brain tumours. Urteste now has a pipeline of 12 prototype diagnostic tests for the following cancers: pancreatic, brain, breast, stomach, bile ducts, ovary, endometrial, kidney, colorectal, lung, liver and prostate accounting collectively for nearly 70% of all cancer deaths worldwide. In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its project PANURI, a test for pancreatic cancer. Urteste’s breakthrough technology allows for early detection of cancer by measuring the activity of enzymes present in urine using proprietary synthetic peptides. One urine sample can be used to screen for many types of cancers. Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours. The diagnostic process is automated to minimize the likelihood of human error. PANURI - the pancreatic cancer test is Urteste's most advanced project. Pancreatic cancer is one of the worst prognosis cancers. A proof-of-concept study of 322 participants confirmed the high sensitivity (95.6%) and specificity (95.5%) of the PANURI test. Urteste is currently undergoing an FDA Q-Submission programme. In the MULTI-CANCER project, Urteste is developing a diverse portfolio of tests. The company already has prototypes of 12 diagnostic tests for the most common cancers. In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests. The company will then focus on preparing for clinical trials. Urteste holds polish patents and international patent applications for its technology. Urteste's patent strategy is to seek patent protection in countries that collectively generate around 90% of global GDP.お知らせ • May 21Urteste S.A., Annual General Meeting, Jun 14, 2024Urteste S.A., Annual General Meeting, Jun 14, 2024.お知らせ • Jan 19+ 3 more updatesUrteste S.A. to Report Q3, 2024 Results on Nov 28, 2024Urteste S.A. announced that they will report Q3, 2024 results on Nov 28, 2024New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (zł155.1m market cap, or US$38.0m).お知らせ • May 31Urteste S.A., Annual General Meeting, Jun 22, 2023Urteste S.A., Annual General Meeting, Jun 22, 2023, at 14:00 Central European Standard Time.お知らせ • May 28+ 1 more updateUrteste S.A. to Report First Half, 2023 Results on Sep 29, 2023Urteste S.A. announced that they will report first half, 2023 results on Sep 29, 2023お知らせ • Jan 26+ 3 more updatesUrteste S.A. to Report Q3, 2023 Results on Nov 13, 2023Urteste S.A. announced that they will report Q3, 2023 results on Nov 13, 2023株主還元URTPL BiotechsPL 市場7D-3.4%-0.4%3.1%1Y-45.3%-10.4%27.8%株主還元を見る業界別リターン: URT過去 1 年間で-10.4 % の収益を上げたPolish Biotechs業界を下回りました。リターン対市場: URTは、過去 1 年間で27.8 % のリターンを上げたPolish市場を下回りました。価格変動Is URT's price volatile compared to industry and market?URT volatilityURT Average Weekly Movement7.6%Biotechs Industry Average Movement5.4%Market Average Movement5.3%10% most volatile stocks in PL Market11.0%10% least volatile stocks in PL Market3.2%安定した株価: URTの株価は、 Polish市場と比較して過去 3 か月間で変動しています。時間の経過による変動: URTの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてPolishの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト202136Grzegorz Stefanskiurteste.euUrteste S.A.は癌の診断テストの研究開発に従事している。膵臓がん、前立腺がん、腎臓がん、大腸がん、肝臓がん、胆道がん、胃がん、肺がん、食道がん、卵巣がん、子宮内膜がん、血液がん、乳がん、神経系がんの診断検査を提供している。同社は2021年に法人化され、ポーランドのグダニスクに本社を置いている。もっと見るUrteste S.A. 基礎のまとめUrteste の収益と売上を時価総額と比較するとどうか。URT 基礎統計学時価総額zł60.90m収益（TTM）-zł5.98m売上高(TTM)zł2.50m24.3xP/Sレシオ-10.2xPER（株価収益率URT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計URT 損益計算書（TTM）収益zł2.50m売上原価zł256.00k売上総利益zł2.25mその他の費用zł8.23m収益-zł5.98m直近の収益報告Dec 31, 2025次回決算日Sep 29, 2026一株当たり利益（EPS）-4.24グロス・マージン89.78%純利益率-238.86%有利子負債／自己資本比率8.3%URT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 06:54終値2026/05/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Urteste S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Sylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.
New Risk • Dec 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł5.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.8m revenue, or US$496k). Minor Risk Market cap is less than US$100m (zł49.3m market cap, or US$13.6m).
お知らせ • Aug 25Urteste S.A. to Report First Half, 2025 Results on Sep 29, 2025Urteste S.A. announced that they will report first half, 2025 results on Sep 29, 2025
お知らせ • Jul 21Urteste S.A. Completes the Development Phase of Panuri Test and Reached Technological Readiness for Clinical Performance StudyUrteste S.A. has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer - one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents with confirmed structure and purity, as well as reproducible test performance. The result-reading process has also been automated. As a result, the Panuri test complies with the IVDR - Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł15m free cash flow). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.5m revenue, or US$410k). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (zł80.6m market cap, or US$21.5m).
お知らせ • May 29Urteste S.A., Annual General Meeting, Jun 25, 2025Urteste S.A., Annual General Meeting, Jun 25, 2025.
分析記事 • May 27Here's Why We're Watching Urteste's (WSE:URT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Dec 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł5.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.8m revenue, or US$496k). Minor Risk Market cap is less than US$100m (zł49.3m market cap, or US$13.6m).
お知らせ • Aug 25Urteste S.A. to Report First Half, 2025 Results on Sep 29, 2025Urteste S.A. announced that they will report first half, 2025 results on Sep 29, 2025
お知らせ • Jul 21Urteste S.A. Completes the Development Phase of Panuri Test and Reached Technological Readiness for Clinical Performance StudyUrteste S.A. has completed the development phase of its Panuri test and reached technological readiness for clinical performance study. The test is designed to detect pancreatic cancer - one of the most difficult cancers to diagnose. Clinical study in Europe are scheduled to begin in the third quarter of 2025. Urteste has developed all components of the Panuri test, including buffers, reagents, and a positive control. In-process control was conducted, and the pre-analytical phase was optimized, resulting in high-quality reagents with confirmed structure and purity, as well as reproducible test performance. The result-reading process has also been automated. As a result, the Panuri test complies with the IVDR - Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł15m free cash flow). Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (zł1.5m revenue, or US$410k). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (zł80.6m market cap, or US$21.5m).
お知らせ • May 29Urteste S.A., Annual General Meeting, Jun 25, 2025Urteste S.A., Annual General Meeting, Jun 25, 2025.
分析記事 • May 27Here's Why We're Watching Urteste's (WSE:URT) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Dec 07Is Urteste (WSE:URT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Jul 19Urteste (WSE:URT) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
お知らせ • May 29Urteste S.A. Successfully Develops A Prototype Urine-Based Diagnostic Test for Detecting Brain TumoursUrteste S.A. developed a prototype IVD test for detecting brain tumours. Urteste now has a pipeline of 12 prototype diagnostic tests for the following cancers: pancreatic, brain, breast, stomach, bile ducts, ovary, endometrial, kidney, colorectal, lung, liver and prostate accounting collectively for nearly 70% of all cancer deaths worldwide. In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its project PANURI, a test for pancreatic cancer. Urteste’s breakthrough technology allows for early detection of cancer by measuring the activity of enzymes present in urine using proprietary synthetic peptides. One urine sample can be used to screen for many types of cancers. Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours. The diagnostic process is automated to minimize the likelihood of human error. PANURI - the pancreatic cancer test is Urteste's most advanced project. Pancreatic cancer is one of the worst prognosis cancers. A proof-of-concept study of 322 participants confirmed the high sensitivity (95.6%) and specificity (95.5%) of the PANURI test. Urteste is currently undergoing an FDA Q-Submission programme. In the MULTI-CANCER project, Urteste is developing a diverse portfolio of tests. The company already has prototypes of 12 diagnostic tests for the most common cancers. In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests. The company will then focus on preparing for clinical trials. Urteste holds polish patents and international patent applications for its technology. Urteste's patent strategy is to seek patent protection in countries that collectively generate around 90% of global GDP.
お知らせ • May 21Urteste S.A., Annual General Meeting, Jun 14, 2024Urteste S.A., Annual General Meeting, Jun 14, 2024.
お知らせ • Jan 19+ 3 more updatesUrteste S.A. to Report Q3, 2024 Results on Nov 28, 2024Urteste S.A. announced that they will report Q3, 2024 results on Nov 28, 2024
New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (zł155.1m market cap, or US$38.0m).
お知らせ • May 31Urteste S.A., Annual General Meeting, Jun 22, 2023Urteste S.A., Annual General Meeting, Jun 22, 2023, at 14:00 Central European Standard Time.
お知らせ • May 28+ 1 more updateUrteste S.A. to Report First Half, 2023 Results on Sep 29, 2023Urteste S.A. announced that they will report first half, 2023 results on Sep 29, 2023
お知らせ • Jan 26+ 3 more updatesUrteste S.A. to Report Q3, 2023 Results on Nov 13, 2023Urteste S.A. announced that they will report Q3, 2023 results on Nov 13, 2023
